Clinical Trials Logo

Clinical Trial Summary

A mono centre study to evaluate the efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.


Clinical Trial Description

Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating from thyroid C cells. Neuroendocrine tumors have been demonstrated to express somatostatin receptors as well as mTOR pathway. The somatostatin analogues now available (octreotide and lanreotide) act preferentially through the somatostatin receptor subtype 2 (sst2). In MTC, these compounds have been reported to exert anti-secretive effects on calcitonin but no anti-proliferative effects.SOM230 (pasireotide) is a new somatostatin analogue showing a peculiar binding profile with high affinity for sst1, sst2, sst3, sst5. Preliminary data show SOM230 to be effective in a phase II study on patients with metastatic carcinoid. RAD001 (everolimus) is a novel agent that interacts with mTOR. It was demonstrated to inhibit tumor growth in neuroendocrine tumor cell lines. Some clinical trials have explored the efficacy of a combined therapy with RAD001 plus octreotide in patients with digestive neuroendocrine tumors, highlighting encouraging results in term of tumor control.In particular, octreotide and RAD001 seem to show a synergistic activity in inhibiting neuroendocrine tumor proliferation. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01625520
Study type Interventional
Source Federico II University
Contact
Status Completed
Phase Phase 2
Start date February 2012

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03643055 - 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06277180 - 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC N/A
Withdrawn NCT04760288 - A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Phase 3
Not yet recruiting NCT06079723 - A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
Recruiting NCT01739634 - The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Phase 1/Phase 2
Recruiting NCT03157128 - A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Phase 1/Phase 2
Completed NCT02856347 - Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin N/A
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04280081 - A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Phase 2
Not yet recruiting NCT06292988 - Predictive Factors for Medullary Thyroid Cancer Aggressiveness
Completed NCT01757470 - Vandetanib Risk Minimisation Effectiveness N/A
Recruiting NCT05830500 - Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma Phase 4
Recruiting NCT03899792 - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Phase 1/Phase 2
Recruiting NCT01660984 - Natural History Study of Children and Adults With Medullary Thyroid Cancer
Withdrawn NCT03838692 - Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Phase 2
Terminated NCT02363647 - Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer N/A
Terminated NCT00582712 - An Initial Study of Lithium in Patients With Medullary Thyroid Cancer Phase 2
Recruiting NCT06141369 - Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) N/A
Completed NCT06243965 - Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?